Neuren Pharmaceuticals Limited
NURPF · OTC
Company research
Neuren Pharmaceuticals Limited (ASX: NEU; OTC: NURPF) is an Australia-based biopharmaceutical company focused on developing innovative therapies for serious neurodevelopmental disorders that emerge in early childhood. The company's lead product, DAYBUE (trofinetide), has received FDA approval for the treatment of Rett syndrome in adults and pediatric patients aged two years and older, with commercialisation in North America conducted through an exclusive licensing agreement with Acadia Pharmaceuticals Inc. Neuren's second drug candidate, NNZ-2591, is currently progressing through Phase 2 clinical trials targeting a range of rare neurodevelopmental conditions including Phelan-McDermid, Angelman, and Pitt Hopkins syndromes, with all programs having received orphan drug designation in the United States. Incorporated in 2001 and headquartered in Camberwell, Victoria, Australia, Neuren operates across two reportable segments — Commercial Products and Research and Development — and reported total revenue of approximately AUD $224.3 million in 2025.
Research reports
Algorithm-driven quantitative report that issues a strong sell recommendation on NURPF over a 90‑day horizon, highlighting alarmed investor sentiment, oversold momentum (low RSI), weak risk‑adjusted returns, and stretched valuation and profitability metrics relative to peers despite the stock screening as undervalued on some measures.
Simply Wall St · February 27, 2026Neuren Pharmaceuticals FY 2025 Margin Strength Tests Earnings Quality ConcernsArticle emphasizes Neuren’s very high recent net margins and strong trailing earnings growth, but warns that these depend heavily on non‑cash items and coincide with forecast revenue decline, producing a large gap between the current share price, consensus price target, and DCF‑based fair value and leaving the sustainability of current profitability open to question.